|
|
|
Company News
|
ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual Meeting
ARIAD Pharmaceuticals
(May 15, 2013)
|
What is a special protocol assessment worth, anyway?
(May 14, 2013)
|
ARIAD to Present at UBS Global Healthcare Conference
ARIAD Pharmaceuticals
(May 13, 2013)
|
ARIAD Reports First Quarter 2013 Financial Results and Development Progress
ARIAD Pharmaceuticals
(May 07, 2013)
|
ARIAD to Present at Bank of America Merrill Lynch Healthcare Conference
ARIAD Pharmaceuticals
(May 06, 2013)
|
ARIAD to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013
ARIAD Pharmaceuticals
(April 23, 2013)
|
ARIAD Presents New Preclinical Data Showing AP26113 Inhibits Clinically Relevant Mutants of ALK and ROS1
ARIAD Pharmaceuticals
(April 10, 2013)
|
ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors
ARIAD Pharmaceuticals
(April 09, 2013)
|
ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Oncogenic Drivers of Non-Small Cell Lung Cancer
ARIAD Pharmaceuticals
(April 08, 2013)
|
CORRECTING and REPLACING ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ET
ARIAD Pharmaceuticals
(April 04, 2013)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.
|
|
Company Profile
|
| Profile
|
ARIAD Pharmaceuticals (ARIA) is a Massachusetts based biotechnology company focused on development & marketing of anti-cancer drugs that function by regulating the cell signalling pathways. |
| Listed or Private Company
|
Listed |
| Company Classification
|
Biotechnology; Genomics |
| Country
|
USA
|
| Company Website
|
Website
|
|
Full Company Profile Information
|
PARTNERING OPPORTUNITIES (Click on Product Name for Full Details)
|
| Product
|
Available for Partnering
|
Opportunity Comment
|
Available USA
|
Available Europe
|
Available Japan
|
Available RoW
|
Markets Detail
|
| Iclusig
|
Yes |
Company plans for commercialisation of ponatinib on its own in US & potentially in Europe and a regional partnership for the product in select ex-US markets. |
No |
Yes |
Yes |
Yes |
WW ex USA |
|
|
EventAnalyzer - Last Key Event
|
| Closing Price DateClosing Price Date
|
EventAnalyzer Note
|
Market Cap (US $m)
|
Change (%)
|
Change (+$m)
|
| 03/01/2013 |
3 Jan: UBS maintains "buy" rating but lowers price target from $29 to $26. |
3,291 |
-1.7% |
-57 |
|
|
EvaluatePharma® Coverage of Marketed and Pipeline Products
|
|
|
|
Welcome
Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.
Explore Evaluate
Partnering
EvaluatePharma® now includes Partnering Opportunities - products available for licensing.
Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.
Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.
Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.
| |
 |
| EP Vantage - last 6 months |
 |
 |
 |
|
|
|
Register to access more FREE content:
- 2011 Product Sales analysis
- 2011 Pharmaceutical Sales
- 2011 Market Share & Global Ranking
- Download to Excel
- Search 2 yrs of company press releases
Register for Free Analysis
Register to access more free insights and analysis from Evaluate.
Register Now
|
|
|
|